A detailed history of Barclays PLC transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, Barclays PLC holds 20,473 shares of OVID stock, worth $22,929. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,473
Previous 42,136 51.41%
Holding current value
$22,929
Previous $128,000 88.28%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.7 - $3.34 $15,164 - $72,354
-21,663 Reduced 51.41%
20,473 $15,000
Q1 2024

May 15, 2024

SELL
$2.72 - $4.04 $108,593 - $161,292
-39,924 Reduced 48.65%
42,136 $128,000
Q4 2023

Feb 15, 2024

BUY
$2.98 - $3.78 $212,414 - $269,438
71,280 Added 661.22%
82,060 $264,000
Q3 2023

Nov 07, 2023

SELL
$3.23 - $3.97 $3,795 - $4,664
-1,175 Reduced 9.83%
10,780 $41,000
Q2 2023

Aug 03, 2023

BUY
$2.53 - $3.89 $30,246 - $46,504
11,955 New
11,955 $40,000
Q4 2021

Feb 14, 2022

SELL
$3.13 - $3.73 $25,722 - $30,653
-8,218 Closed
0 $0
Q3 2021

Nov 09, 2021

SELL
$3.31 - $4.04 $89,399 - $109,116
-27,009 Reduced 76.67%
8,218 $28,000
Q2 2021

Aug 13, 2021

SELL
$3.3 - $4.49 $16,005 - $21,776
-4,850 Reduced 12.1%
35,227 $137,000
Q1 2021

May 13, 2021

BUY
$2.42 - $4.47 $59,817 - $110,489
24,718 Added 160.93%
40,077 $161,000
Q4 2020

Feb 11, 2021

SELL
$2.28 - $6.84 $23,429 - $70,287
-10,276 Reduced 40.09%
15,359 $35,000
Q3 2020

Nov 12, 2020

BUY
$5.39 - $8.24 $11,108 - $16,982
2,061 Added 8.74%
25,635 $147,000
Q2 2020

Aug 12, 2020

BUY
$2.67 - $7.91 $62,942 - $186,470
23,574 New
23,574 $173,000
Q3 2019

Nov 14, 2019

SELL
$1.76 - $3.51 $469 - $937
-267 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$1.59 - $2.14 $5,495 - $7,395
-3,456 Reduced 92.83%
267 $0
Q1 2019

May 15, 2019

BUY
$1.77 - $3.56 $6,589 - $13,253
3,723 New
3,723 $7,000
Q4 2018

Feb 14, 2019

SELL
$2.42 - $6.6 $11,949 - $32,590
-4,938 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$5.6 - $11.0 $19,700 - $38,698
3,518 Added 247.75%
4,938 $28,000
Q2 2018

Aug 14, 2018

SELL
$6.16 - $10.14 $6,886 - $11,336
-1,118 Reduced 44.05%
1,420 $11,000
Q1 2018

May 15, 2018

BUY
$6.53 - $9.82 $11,342 - $17,057
1,737 Added 216.85%
2,538 $18,000
Q4 2017

Feb 14, 2018

BUY
$6.12 - $12.31 $4,179 - $8,407
683 Added 578.81%
801 $8,000
Q3 2017

Nov 14, 2017

BUY
$5.32 - $9.77 $627 - $1,152
118
118 $1,000

Others Institutions Holding OVID

About Ovid Therapeutics Inc.


  • Ticker OVID
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,419,400
  • Market Cap $78.9M
  • Description
  • Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...
More about OVID
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.